Last reviewed · How we verify

NCT07368673

Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial

Completed Phase 4 Last updated 26 January 2026
What this trial tests

Phase 4 trial testing ruxolitinib cream in Vitiligo in 120 participants. Completed in 5 January 2026.

Timeline
6 April 2025
Primary endpoint
31 December 2025
5 January 2026

Quick facts

Lead sponsorDow University of Health Sciences
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment120
Start date6 April 2025
Primary completion31 December 2025
Estimated completion5 January 2026
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Dow University of Health Sciences

Who can join

Adults 18 to 65, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

this randomized controlled trial aims to compare the effectiveness and safety of ruxolitinib monotherapy versus its combination with topical tacrolimus or topical corticosteroids in patients with non-segmental vitiligo involving less than 10% body surface area. A total of 120 adult patients will be randomized into three treatment groups and followed for 24 weeks. Treatment response will be evaluated using validated scoring systems including the Vitiligo Area Severity Index (VASI), Vitiligo European Task Force (VETF) staging, and Physician Global Assessment. The findings may help optimize topical treatment strategies for vitiligo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ruxolitinib cream

Trials testing the same drug.

Other recruiting trials for Vitiligo

Currently open trials in the same condition.

Other Dow University of Health Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07368673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing